Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Autoimmune Disorders

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 71 articles: HTML format Text format

Single Articles

August 2018
1. SEBASTIAN LOPEZ-CHIRIBOGA A, Klein C, Zekeridou A, McKeon A, et al
   LGI1 and CASPR2 Neurological Autoimmunity in Children.
   Ann Neurol. 2018 Aug 3. doi: 10.1002/ana.25310.
   PubMed     Text format     Abstract available
   
   
   July 2018
2. FUJII T, Yamasaki R, Iinuma K, Tsuchimoto D, et al
   A novel autoantibody against plexin D1 in patients with neuropathic pain.
   Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25279.
   PubMed     Text format     Abstract available
   
   
   June 2018
3. JIA X, Madireddy L, Caillier S, Santaniello A, et al
   Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
   Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25263.
   PubMed     Text format     Abstract available
   
   
   May 2018
4. DISANTO G, Zecca C, MacLachlan S, Sacco R, et al
   Prodromal symptoms of multiple sclerosis in primary care.
   Ann Neurol. 2018 May 8. doi: 10.1002/ana.25247.
   PubMed     Text format     Abstract available
   
   
   April 2018
5. TANKOU SK, Regev K, Healy BC, Tjon E, et al
   A probiotic modulates the microbiome and immunity in multiple sclerosis.
   Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244.
   PubMed     Text format     Abstract available
   
   
   
6. VOGRIG A, Brigo F, Valente M, Gigli GL, et al
   Epidemiology of autoimmune versus infectious encephalitis.
   Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25229.
   PubMed     Text format    
   
   
   
7. DUBEY D, Pittock SJ, Toledano M, Flanagan EP, et al
   Reply to "Epidemiology of autoimmune versus infectious encephalitis".
   Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25230.
   PubMed     Text format    
   
   
   March 2018
8. CRAMER SP, Simonsen HJ, Varatharaj A, Galea I, et al
   Permeability of the blood-brain barrier predicts no evidence of disease activity at two years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
   Ann Neurol. 2018 Mar 31. doi: 10.1002/ana.25219.
   PubMed     Text format     Abstract available
   
   
   
9. ANTEL J
   The reality of "ghosts" in authorship of clinical trials in multiple sclerosis.
   Ann Neurol. 2018 Mar 13. doi: 10.1002/ana.25199.
   PubMed     Text format    
   
   
   
10. COLES A
    Authorship of phase 3 trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25203.
    PubMed     Text format    
    
    
    
11. MAGLIOZZI R, Howell OW, Nicholas R, Cruciani C, et al
    Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25197.
    PubMed     Text format     Abstract available
    
    
    January 2018
12. ESHAGHI A, Prados F, Brownlee W, Altmann DR, et al
    Deep grey matter volume loss drives disability worsening in multiple sclerosis.
    Ann Neurol. 2018 Jan 13. doi: 10.1002/ana.25145.
    PubMed     Text format     Abstract available
    
    
    
13. DUBEY D, Pittock SJ, Kelly CR, McKeon A, et al
    Autoimmune Encephalitis Epidemiology and a comparison to Infectious Encephalitis.
    Ann Neurol. 2018 Jan 2. doi: 10.1002/ana.25131.
    PubMed     Text format     Abstract available
    
    
    December 2017
14. GILES DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, et al
    Myeloid cell plasticity in the evolution of central nervous system autoimmunity.
    Ann Neurol. 2017 Dec 28. doi: 10.1002/ana.25128.
    PubMed     Text format     Abstract available
    
    
    
15. GREENFIELD AL, Hauser SL
    B Cell Therapy for Multiple Sclerosis: Entering an Era.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25119.
    PubMed     Text format     Abstract available
    
    
    
16. PATTERSON KR, Dalmau J, Lancaster E
    Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25120.
    PubMed     Text format     Abstract available
    
    
    November 2017
17. KANAI T, Uzawa A, Sato Y, Suzuki S, et al
    A clinical predictive score for postoperative myasthenic crisis.
    Ann Neurol. 2017;82:841-849.
    PubMed     Text format     Abstract available
    
    
    October 2017
18. BARBOUR C, Kosa P, Komori M, Tanigawa M, et al
    Molecular-based diagnosis of Multiple Sclerosis and its progressive stage.
    Ann Neurol. 2017 Oct 23. doi: 10.1002/ana.25083.
    PubMed     Text format     Abstract available
    
    
    
19. AZODI S, Nair G, Enose-Akahata Y, Charlip E, et al
    Imaging Spinal Cord Atrophy in Progressive Myelopathies: HTLV-I Associated Neurologic Disease (HAM/TSP) and Multiple Sclerosis (MS).
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25072.
    PubMed     Text format     Abstract available
    
    
    
20. JENDE JME, Hauck GH, Diem R, Weiler M, et al
    Peripheral nerve involvement in multiple sclerosis Demonstration by magnetic resonance neurography.
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25068.
    PubMed     Text format     Abstract available
    
    
    
21. MAINERO C, Louapre C
    Unravelling cortical pathology in multiple sclerosis using the T1-/T2-weighted ratio?
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25063.
    PubMed     Text format    
    
    
    
22. WIJNANDS JMA, Tremlett H
    Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25061.
    PubMed     Text format    
    
    
    
23. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Reply to: Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25062.
    PubMed     Text format    
    
    
    September 2017
24. FITZGERALD KC, Munger KL, Ascherio A
    Reply to "Stratified analyses are necessary to verify the influence of salt intake in multiple sclerosis".
    Ann Neurol. 2017 Sep 29. doi: 10.1002/ana.25055.
    PubMed     Text format    
    
    
    
25. ZAHEDNASAB H, Harirchian MH, Karampoor S, Keyvani H, et al
    MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25037.
    PubMed     Text format    
    
    
    
26. FISSOLO N, Pignolet B, Brassat D, Comabella M, et al
    Reply: MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25039.
    PubMed     Text format    
    
    
    
27. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Concussion in adolescence and risk of multiple sclerosis.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25036.
    PubMed     Text format     Abstract available
    
    
    August 2017
28. NAKAMURA K, Chen JT, Ontaneda D, Fox RJ, et al
    T1-/T2-weighted ratio differs in demyelinated cortex of multiple sclerosis.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25019.
    PubMed     Text format     Abstract available
    
    
    
29. RIGHART R, Biberacher V, Jonkman LE, Klaver R, et al
    Cortical pathology in MS detected by the T1/T2-weighted ratio from routine MRI.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25020.
    PubMed     Text format     Abstract available
    
    
    
30. DALAKAS MC, Rakocevic G, Dambrosia JM, Alexopoulos H, et al
    A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.
    Ann Neurol. 2017;82:271-277.
    PubMed     Text format     Abstract available
    
    
    July 2017
31. YATES RL, Esiri MM, Palace J, Jacobs B, et al
    Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.
    Ann Neurol. 2017 Jul 18. doi: 10.1002/ana.24997.
    PubMed     Text format     Abstract available
    
    
    
32. FISSOLO N, Pignolet B, Matute-Blanch C, Trivino JC, et al
    MMP9 is decreased in natalizumab-treated MS patients at risk for PML.
    Ann Neurol. 2017 Jul 6. doi: 10.1002/ana.24987.
    PubMed     Text format     Abstract available
    
    
    May 2017
33. FITZGERALD KC, Munger KL, Hartung HP, Freedman MS, et al
    Sodium intake and multiple sclerosis activity and progression in BENEFIT.
    Ann Neurol. 2017 May 26. doi: 10.1002/ana.24965.
    PubMed     Text format     Abstract available
    
    
    
34. DISANTO G, Barro C, Benkert P, Naegelin Y, et al
    Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Ann Neurol. 2017 May 16. doi: 10.1002/ana.24954.
    PubMed     Text format     Abstract available
    
    
    
35. CUI QL, Khan D, Rone M, Rao V, et al
    Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?
    Ann Neurol. 2017 May 3. doi: 10.1002/ana.24944.
    PubMed     Text format     Abstract available
    
    
    
36. IAFFALDANO P, Simone M, Lucisano G, Ghezzi A, et al
    Prognostic indicators in pediatric clinically isolated syndrome.
    Ann Neurol. 2017;81:729-739.
    PubMed     Text format     Abstract available
    
    
    April 2017
37. ANDRODIAS G, Bernard E, Biotti D, Collongues N, et al
    Multiple sclerosis broke my heart.
    Ann Neurol. 2017 Apr 24. doi: 10.1002/ana.24935.
    PubMed     Text format     Abstract available
    
    
    
38. SELMAJ I, Cichalewska M, Namiecinska M, Galazka G, et al
    Global Exosome Transcriptome Profiling Reveals Biomarkers for Multiple Sclerosis.
    Ann Neurol. 2017 Apr 15. doi: 10.1002/ana.24931.
    PubMed     Text format     Abstract available
    
    
    March 2017
39. TAWARA N, Yamashita S, Zhang X, Korogi M, et al
    Pathomechanisms of anti-cN1A autoantibodies in sporadic inclusion body myositis.
    Ann Neurol. 2017 Mar 20. doi: 10.1002/ana.24919.
    PubMed     Text format     Abstract available
    
    
    
40. TREMLETT H, Bauer KC, Appel-Cresswell S, Finlay BB, et al
    The gut microbiome in human neurological disease: A review.
    Ann Neurol. 2017;81:369-382.
    PubMed     Text format     Abstract available
    
    
    February 2017
41. AROUCHE-DELAPERCHE L, Allenbach Y, Amelin D, Preusse C, et al
    Pathogenic role of anti-SRP and anti-HMGCR antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies.
    Ann Neurol. 2017 Feb 22. doi: 10.1002/ana.24902.
    PubMed     Text format     Abstract available
    
    
    
42. KIM TJ, Lee ST, Moon J, Sunwoo JS, et al
    Anti-LGI1 encephalitis is associated with unique HLA subtypes.
    Ann Neurol. 2017;81:183-192.
    PubMed     Text format     Abstract available
    
    
    January 2017
43. GONZALEZ-BILLAULT C
    The identity of the PCA-2 autoantibody antigen is finally revealed.
    Ann Neurol. 2017 Jan 30. doi: 10.1002/ana.24884.
    PubMed     Text format    
    
    
    
44. FLANAGAN EP, Hinson SR, Lennon VA, Fang B, et al
    GFAP-IgG as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients.
    Ann Neurol. 2017 Jan 24. doi: 10.1002/ana.24881.
    PubMed     Text format     Abstract available
    
    
    December 2016
45. HERRANZ E, Hooker JM, Izquierdo-Garcia D, Loggia ML, et al
    11 C-PBR28 increase in multiple sclerosis reflects neuroinflammation.
    Ann Neurol. 2016 Dec 29. doi: 10.1002/ana.24865.
    PubMed     Text format    
    
    
    
46. RAFFEL J, Sridharan S, Nicholas R
    [11 C]PBR-28 PET in multiple sclerosis: Neuroinflammation or otherwise?
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24853.
    PubMed     Text format    
    
    
    October 2016
47. GOBEL K, Kraft P, Pankratz S, Gross CC, et al
    Prothrombin and factor X are elevated in multiple sclerosis patients.
    Ann Neurol. 2016 Oct 24. doi: 10.1002/ana.24807.
    PubMed     Text format     Abstract available
    
    
    September 2016
48. HERRANZ E, Gianni C, Louapre C, Treaba CA, et al
    The neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Ann Neurol. 2016 Sep 30. doi: 10.1002/ana.24791.
    PubMed     Text format     Abstract available
    
    
    August 2016
49. CORTESE M, Riise T, Bjornevik K, Bhan A, et al
    Pre-clinical disease activity in multiple sclerosis- a prospective study on cognitive performance prior to first symptom.
    Ann Neurol. 2016 Aug 23. doi: 10.1002/ana.24769.
    PubMed     Text format     Abstract available
    
    
    
50. MEYER SAUTEUR PM, Huizinga R, Tio-Gillen AP, Roodbol J, et al
    Mycoplasma pneumoniae triggering the Guillain-Barre syndrome: A case-control study.
    Ann Neurol. 2016 Aug 4. doi: 10.1002/ana.24755.
    PubMed     Text format     Abstract available
    
    
    July 2016
51. CREE B, Gourraud PA, Oksenberg JR, Bevan C, et al
    Long-term evolution of multiple sclerosis disability in the treatment era.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24747.
    PubMed     Text format     Abstract available
    
    
    
52. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Neuroanatomic Correlates of Female Sexual Dysfunction in Multiple Sclerosis.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24746.
    PubMed     Text format     Abstract available
    
    
    
53. WHITE MK, Wollebo HS, Beckham JD, Tyler KL, et al
    Zika virus: An emergent neuropathological agent.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24748.
    PubMed     Text format     Abstract available
    
    
    June 2016
54. GERDES LA, Held K, Beltran E, Berking C, et al
    CTLA-4 as immunological checkpoint in the development of multiple sclerosis.
    Ann Neurol. 2016 Jun 28. doi: 10.1002/ana.24715.
    PubMed     Text format     Abstract available
    
    
    May 2016
55. JOKUBAITIS VG, Spelman T, Kalincik T, Lorscheider J, et al
    Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
    Ann Neurol. 2016 May 4. doi: 10.1002/ana.24682.
    PubMed     Text format     Abstract available
    
    
    April 2016
56. HARSCHNITZ O, van den Berg LH, Johansen LE, Jansen MD, et al
    Autoantibody pathogenicity in a multifocal motor neuropathy iPSC-derived model.
    Ann Neurol. 2016 Apr 30. doi: 10.1002/ana.24680.
    PubMed     Text format     Abstract available
    
    
    
57. BODINI B, Veronese M, Turkheimer F, Stankoff B, et al
    Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis.
    Ann Neurol. 2016 Apr 21. doi: 10.1002/ana.24667.
    PubMed     Text format    
    
    
    
58. MATIAS-GUIU JA, Cabrera-Martin MN, Oreja-Guevara C, Carreras JL, et al
    PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
    Ann Neurol. 2016 Apr 21. doi: 10.1002/ana.24666.
    PubMed     Text format    
    
    
    
59. HOKARI M, Yokoseki A, Arakawa M, Saji E, et al
    Clinicopathological features in anterior visual pathway in neuromyelitis optica.
    Ann Neurol. 2016;79:605-24.
    PubMed     Text format     Abstract available
    
    
    March 2016
60. ALPING P, Frisell T, Novakova L, Islam-Jakobsson P, et al
    Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
    Ann Neurol. 2016 Mar 31. doi: 10.1002/ana.24651.
    PubMed     Text format     Abstract available
    
    
    
61. LASSMANN H
    Demyelination and Neurodegeneration in Multiple Sclerosis: The Role of Hypoxia.
    Ann Neurol. 2016 Mar 9. doi: 10.1002/ana.24632.
    PubMed     Text format    
    
    
    
62. JELCIC I, Jelcic I, Kempf C, Largey F, et al
    Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.
    Ann Neurol. 2016;79:404-18.
    PubMed     Text format     Abstract available
    
    
    
63. FLANAGAN EP, Kaufmann TJ, Krecke KN, Aksamit AJ, et al
    Discriminating long myelitis of neuromyelitis optica from sarcoidosis.
    Ann Neurol. 2016;79:437-47.
    PubMed     Text format     Abstract available
    
    
    February 2016
64. BODINI B, Veronese M, Garcia-Lorenzo D, Battaglini M, et al
    Dynamic imaging of individual remyelination profiles in multiple sclerosis.
    Ann Neurol. 2016 Feb 18. doi: 10.1002/ana.24620.
    PubMed     Text format     Abstract available
    
    
    
65. FLANAGAN EP, Cabre P, Weinshenker BG, St Sauver J, et al
    Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.
    Ann Neurol. 2016 Feb 17. doi: 10.1002/ana.24617.
    PubMed     Text format     Abstract available
    
    
    
66. WEINSHENKER BG
    What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?
    Ann Neurol. 2016;79:204-5.
    PubMed     Text format    
    
    
    
67. KLEITER I, Gahlen A, Borisow N, Fischer K, et al
    Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.
    Ann Neurol. 2016;79:206-16.
    PubMed     Text format     Abstract available
    
    
    January 2016
68. DESAI RA, Davies AL, Tachrount M, Kasti M, et al
    Cause and prevention of demyelination in a model multiple sclerosis lesion.
    Ann Neurol. 2016 Jan 27. doi: 10.1002/ana.24607.
    PubMed     Text format     Abstract available
    
    
    November 2015
69. KANTARCI OH, Lebrun C, Siva A, Keegan MB, et al
    Primary Progressive MS evolving from Radiologically Isolated Syndrome.
    Ann Neurol. 2015 Nov 24. doi: 10.1002/ana.24564.
    PubMed     Text format     Abstract available
    
    
    
70. XIA Z, White CC, Owen EK, Von Korff A, et al
    GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
    Ann Neurol. 2015 Nov 19. doi: 10.1002/ana.24560.
    PubMed     Text format     Abstract available
    
    
    
71. SAIDHA S, Al-Louzi O, Ratchford JN, Bhargava P, et al
    Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.
    Ann Neurol. 2015;78:801-13.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: